FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer

The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)‐associated metastatic castrate‐resistant prostate cancer (mCRPC) who have been treated with androgen receptor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Anscher, Mitchell S., Chang, Elaine, Gao, Xin, Gong, Yutao, Weinstock, Chana, Bloomquist, Erik, Adeniyi, Oluseyi, Charlab, Rosane, Zimmerman, Sarah, Serlemitsos‐Day, Maritsa, Ning, Yang Min, Mayrosh, Ruth, Fuller, Barbara, Trentacosti, Ann Marie, Gallagher, Pamela, Bijwaard, Karen, Philip, Reena, Ghosh, Soma, Fahnbulleh, Frances, Diggs, Felicia, Arora, Shaily, Goldberg, Kirsten B., Tang, Shenghui, Amiri‐Kordestani, Laleh, Pazdur, Richard, Ibrahim, Amna, Beaver, Julia A.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Regulatory Issues: FDA
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873319/
https://ncbi.nlm.nih.gov/pubmed/33145877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13585
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items